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Abstract
Background: Low-and middle-income countries are facing both a mounting burden of cardiovascular disease
(CVD) as well as severe resource constraints that keep them from emulating some of the extensive strategies
pursued in high-income countries. There is thus an urgency to identify and implement those interventions that
help reap the biggest reductions of the CVD burden, given low resource levels. What are the interventions to
combat CVDs that represent good “value for money” in low-and middle-income countries? This study reviews the
evidence-base on economic evaluations of interventions located in those countries.
Methods: We conducted a systematic literature review of journal articles published until 2009, based on a
comprehensive key-word based search in generic and specialized electronic databases, accompanied by manual
searches of expert databases. The search strategy consisted of freetext and MeSH terms related to economic
evaluation and cardiovascular disease. Two independent reviewers verified fulfillment of inclusion criteria and
extracted study characteristics.
Results: Thirty-three studies met the selection criteria. We find a growing research interest, in particular in most
recent years, if from a very low baseline. Most interventions fall under the category primary prevention, as opposed
to case management or secondary prevention. Across the spectrum of interventions, pharmaceutical strategies
have been the predominant focus, and, taken at face value, these show significant positive economic evidence,
specifically when compared to the counterfactual of no interventions. Only a few studies consider non-clinical
interventions, at population level. Almost half of the studies have modelled the intervention effectiveness based on
existing risk-factor information and effectiveness evidence from high-income countries.
Conclusion: The cost-effectiveness evidence on CVD interventions in developing countries is growing, but remains
scarce, and is biased towards pharmaceutical interventions. While the burden of cardiovascular disease is growing
in these countries, future research should put greater emphasis on non-clinical interventions than has hitherto
been the case. Significant differences in outcome measures and methodologies prohibit a direct ranking of the
interventions by their degree of cost-effectiveness. Considerable caution should be exercised when transferring
effectiveness estimates from developed countries for the purpose of modelling cost-effectiveness in developing
countries. New local CVD risk factor and intervention follow-up studies are needed. Some pharmaceutical strategies
appear cost-effective while clarifications are needed on the diagnostic approach in single high-risk factor vs.
absolute risk targeting, the role of patient compliance, and the potential public health consequences of large-scale
medicalization.
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Cardiovascular diseases (CVD) make up the largest share
of mortality and burden of disease across developed as
well as developing countries, accounting for 30% of deaths
and about 14% of DALYS lost [1]. In particular in develop-
ing countries the CVD burden is growing. Between 1990
and 2020, coronary heart disease alone is anticipated to
increase by 120% for women and by 137% for men in
developing countries [2]. This epidemiological transition
cannot solely be explained by a rise in life expectancy or
the tackling of other conditions, such as communicable
diseases, but can also be attributed to an increase in risk
factor prevalence in developing countries (in particular in
urban regions), including smoking, risk-increasing dietary
patterns and physical inactivity [3]. These harmful beha-
viors contribute to chronic conditions, such as hyperten-
sion, dyslipidemia and diabetes mellitus, which in turn act
as risk factors for cardiovascular disease. The undoubtedly
mounting burden raises the question, what if anything
could be done about it.
While a number of evidence-based strategies have been
applied in developed countries that have helped reduce
the overall burden, it is an open question whether the
same set of interventions and policies is applicable in a
developing country context. The very limited resources
available to health systems in developing countries,
coupled with a range of health challenges that extend well
beyond CVDs, are obvious key constraints to a major
expansion of services. Taken together, the average level of
expenditures on health care per person in low and middle
income countries only amount to 2.4% of the budget per
person in high income countries [4]. Hence the urgency to
think particularly hard about how to maximize the health
gains of any dollar invested in health care in those heavily
resource constrained countries. In this article we review
the evidence on value for money of interventions that try
to address CVD. Importantly, we only include those stu-
dies in our review that have an explicit focus on one or
more low and middle income country [5].
This is not the first attempt to capture this body of
evidence. We build on major recent efforts to determine
and develop cost-effectiveness estimates, most notably
the 2006 Disease Control Priorities Project (DCP2) and
the WHO initiative on Choosing Interventions that are
cost-effective (CHOICE), which both scrutinize poten-
tially efficient strategies to tackle different chronic dis-
eases and their risk factors in developing regions. To the
best of our knowledge though, there is no recent study
that has looked at this topic in a systematic way. Mulli-
g a ne ta l .[ 6 ]h a v ep r o v i d e dar e v i e wo fe c o n o m i ce v a -
luations of interventions to address non-communicable
diseases in developing countries, concluding that the
evidence base was severely limited and what did exist
was of low quality. The period covered by their review
ended, however, in January 2003 and there is thus a
case for updating the review, here with a focus on CVD,
in the hope that an arguably growing attention to NCDs
in developing countries has also led to more cost-effec-
tiveness research on the topic. To anticipate the basic
thrust of our findings: while there has certainly been a
growing research interest in economic evaluations in
developing countries supporting the investment in cer-
tain drug-based strategies to tackle (part of) the pro-
blem, major research gaps do remain, both in some
geographical regions and in particular in the major
domain of non-clinical interventions.
The focus of this study is to conduct a systematic
review on the cost-effectiveness of interventions to
address cardiovascular disease in developing countries,
both at the population and individual level. We analyze
the characteristics of the evidence, describe and discuss
methods used in the research, and highlight other trends
observed in the literature. In addition to describing what
is known on the basis of the reviewed evidence we also
seek to point out the deficits and gaps in the existing
research. In particular we discuss the challenge of evi-
dence transferability from developed to developing
countries.
Methods
Literature search and study selection
We conducted a disease- and country-specific review, fol-
lowing the methodology of other standard systematic
reviews in this area [5,7] and respecting the PRISMA
statement [8] (Additional file 1). We searched the data-
bases PubMed, EconLit, Embase, and NHS EED for rele-
vant articles. The searches were conducted in August
2010. In addition, the references of retrieved articles were
manually searched for further material. The relevant pub-
lications of the DCP2 project and WHO-CHOICE pro-
gram were completely hand-searched for relevant
articles. As the use of technical terms for indexing inter-
national literature in databases is often inconsistent or
errant we defined a search strategy with high sensitivity
but low specificity. The search strategy consisted of free-
text and MeSH terms related to economic evaluation and
cardiovascular disease. The resulting hits were filtered for
the occurrence of the term “developing countries” or any
country name defined as middle- or low-income country
according to the World Bank definition. The search
included all years up to 2009. The search strings are pro-
vided in the additional material (Additional file 2–Search
strings applied for the review).
Studies were included in the review when they fulfilled
all of the following inclusion criteria:
￿ Published during or prior to the year 2009
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of costs and outcomes of at least two alternatives;
￿ Applied study (trial generating primary data or mod-
eling of secondary data); reviews, letters, abstracts,
methodological and general articles were excluded;
￿ Intervention targeting CVD (CVD endpoint or risk
factor end point)
￿ Assessment of or application to the health care sys-
tem of a developing country as defined by the World
Bank;
￿ Journal articles, i.e., exclusion of books, HTA
reports, grey literature;
￿ Published in English or any language feasible to be
translated by the authors (i.e. German, French, Spanish,
Italian)
We limited our analysis to evaluations published in
journals to assess only those publications that have at
least undergone some basic quality control.
Data extraction and critical appraisal
We developed a checklist to extract data from the full
texts. We collected details on the study design, type of
economic evaluation, intervention target, type of inter-
vention (primary prevention, secondary prevention, and
case management), details of interventions, benefit mea-
sure, sponsorship, economic perspective, details on the
target group, results of the intervention, and the com-
parator used. Quality assessment was based on the
author’s statements on applied methodology. The data
extraction form did not include explicit quality ratings,
i.e. in-depth evaluation whether stated methodology, e.g.
applying societal perspective, was correctly performed.
Since the transferability of results from one region to
another (i.e. from developed to developing countries)
was of particular interest to us, we analyzed in detail the
origin of secondary data used in economic evaluations
that apply models to generate results (epidemiological
data, effectiveness data, da t ao nr e s o u r c eu s e ,d a t ao n
costs). Each paper was independently read by one of
two trained researchers. The researcher decided about
final inclusion of the article. A random sample of 10%
of articles was read by both reviewers to determine the
inerrater reliability. The interrater reliability for inclu-
sion was calculated using Kappa statistics (K). All arti-
cles included were read by the reviewers for extraction
of certain data. After critical appraisal, information col-
lected in data extraction forms were transferred to an
electronic database.
Data analysis
We analyzed the distribution of extracted categories of
economic evaluations. All analyses were performed
using SPSS 16.0 software (SPSS Inc., Chicago IL).
Results
The systematic literature search initially identified 953
candidate articles, of which 81 were selected for fulltext
retrieval (Figure 1 Overview of in- and exclusion of stu-
dies). The majority of articles were discarded at this
initial stage mainly because they were duplicates, or it
was obvious from the bibliographic data that they vio-
lated basic inclusion criteria. Fourty-eight articles were
dropped after the critical appraisal because they failed
one or more inclusion criteria. Finally, 33 articles were
included in the review, of which basic results were
extracted to a table in the additional material (Addi-
tional file 3–Descriptive table of results). Interrater relia-
bility (K) was assessed on a sample of 10% of studies
(n = 9). K was 0.78 for study inclusion, i.e., fulfillment
of all entry criteria, indicating a very good level of agree-
ment [9].
Basic characteristics of included studies
The number of studies conducted has increased sharply
in most recent years, if from a very low baseline. Most
of the studies included in our review were published
within the last 4 years of the review period. While only
13 articles had been published until 2005, there were 20
economic evaluations published from 2006 to 2009.
A majority of 82% (n = 27) of the studies referred to a
single country, compared to 18% (n = 6) of multi-coun-
try evaluations. Most of the single nation studies were
conducted in South Africa (n = 7) and Brazil (n = 7),
followed by Thailand (n = 3). Studies evaluating a
multi-national setting, most often used an aggregated
perspective at the level of WHO or World Bank regions
(n = 4), while two evaluations evaluated strategies in
health care settings based in different countries.
Primary prevention was the most frequent type of
intervention (n = 11), followed by case management of
disease (n = 8) and secondary prevention (n = 5). Sec-
ondary prevention in our study is defined according to
the guidelines of the American Heart Association [10],
i.e. as a preventive intervention after an established
heart disease has been diagnosed (e.g. coronary artery
disease) (Figure 2). Nine studies scrutinized various
types of strategies to combat cardiovascular disease. All
but one case management strategy concerned treatment
(n = 7), one study focused on rehabilitation (n = 1),
while no screening strategy had been evaluated. Studies
in the domain of primary prevention evaluated most
often personal interventions (n = 6) and less often popu-
lation-based interventions (n = 3), while two studies
evaluated an intervention based on both approaches.
A closer look at the detailed characteristics of the inter-
ventions reveals that most measures involved pharma-
ceutical strategies (n = 14), followed by articles
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n=953
Excluded due to violation of basic 
inclusion criteria (e.g. country, disease, 
design, duplicate, etc.)
n=872
Initial inclusion after review of abstracts
n=81
Fulltext retrieval
n=81
Dropped after critical appraisal (n=48)
• No full evaluation (n=20)
• No applied study (n=13)
• No data from developing countries 
(n=6)
• No CVD related endpoint (n=6)
• Other (n=3)
Included evaluations
n=33
Figure 1 Overview of in- and exclusion of studies.
Primary prevention – to reduce the level of one or more risk factors, to reduce the 
probability of initial occurrence of disease (medication for hypertension to prevent 
stroke or heart attack), or to reduce the likelihood of disease when the risk factor is 
already present (prophylaxis for sickle cell anemia)- they can be either population 
based or targeted at the individual as personal intervention
Case Management – to handle the individual case of disease either by Screening 
for Disease, Treatment (Acute Care, Care, Chronic Care) or Rehabilitation, case 
management can include some secondary prevention
Secondary prevention – following the occurrence of disease, either to prevent 
another event of the same kind or to reduce the risk of a different but related event 
(medication to reduce the likelihood of a second coronary event or a first heart 
attack after stroke)
Figure 2 Definition of types of intervention.
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(n = 7), e.g. stent implantation vs. by-pass-graft surgery.
Few studies considered personal health education (n = 3)
or population-based social marketing (n = 2). Four stu-
dies evaluated multiple types of interventions, such as
pharmaceutical interventions, legislation and social mar-
keting combined.
Clustering the studies by intervention targets, the vast
majority of studies (n = 24) aimed at the reduction of risk
factors. Among those, a combination of multiple risk fac-
tors has most often been addressed (n = 11), followed by
interventions targeted at high blood pressure (n = 9).
Other important risk factors, such as smoking (n = 1),
physical inactivity (n = 1), and dyslipidemia (n = 1), were
rarely evaluated. Other intervention targets were revascu-
larization (n = 6) or fatal arrhythmia (n = 1).
Characteristics of economic methods
Looking at the methods of economic evaluations, we
observed that the authors most often used cost-effective-
ness analysis with a clinical outcome (CEA–Clinical),
such as a biomarker or change in health behavior as ben-
efit measure (30%, n = 10). Cost-consequence analysis
(CCA) (n = 10), has been an equally frequently used
method. CCAs usually list benefits and costs of an inter-
vention, without presenting them as a ratio, making it
more complicated to compare different alternatives. Only
about a third of studies used a more comprehensive
approach to scrutinize interventions: those included eight
cost-utility analyses (CUA) and four cost-effectiveness
analyses with “life years gained” (CEA–Life years) as the
benefit measure. The method of cost-benefit analysis
(CBA) has not been applied at all.
In about half of the articles published, modeling was
used to generate costs and benefits (n = 18). By con-
trast, seven studies conducted their evaluation alongside
observational trials and four other evaluations generated
their data alongside randomized controlled trials (RCT).
Four studies used original data generated alongside
other types of studies–mostly cross-sectional studies.
The perspective of an evaluation is important to the
decision maker, in order to determine to whom the costs
occur. This matters because an intervention might be
cost-effective from one point of view (e.g. a societal one),
but not from another (e.g. a health care provider view).
Clearly stating the perspective adopted is therefore an
essential task for the researcher(s) and is consistently
recommended in guidelines of economic evaluations. In
our review, 15 out of 33 studies did not follow this
recommendation. Among those evaluations fulfilling this
task, seven adopted the perspective of the health care
provider and nine applied that of a third party payer (e.g.
health insurance). Only two studies stated to have applied
the patient’s perspective, while no author explicitly
adopted the most comprehensive view–the societal
perspective.
Funding of studies
Most studies (n = 19) did not mention their source of
funding. Those who did, were supported either by the
government (n = 5), the industry (n = 3), or by a foun-
dation (n = 3). Three studies received financial support
by other sources, such as universities or explicitly did
not receive external funding.
Use of secondary data
As mentioned above, 18 studies used modeling to evalu-
ate interventions targeted at the CVD burden in certain
developing countries. We conducted an in depth analy-
sis of secondary data used in those models in order to
determine the level of adaption to the country under
analysis, as well as the reliability of data. Among those
studies stating the source of epidemiological data in
their analysis (n = 17), 14 used available data on disease
burden and mortality from the country or region the
analysis was located in and three articles used this type
of data from developed countries.
A different picture emerges when looking at the data
used for the calculation of intervention effectiveness. All
18 articles used information from studies mainly con-
ducted in developed countries. While twelve studies
based their model on the results of international systema-
tic reviews, five studies relied on a single large rando-
mized controlled trial (RCT) to estimate the effects of an
intervention. One study used the results of an observa-
tional trial as evidence for effectiveness. In those studies
that did state the origin of data for the calculation of
“resource utilization” (n = 15), ten used data from the
country the study was set in, compared to five evalua-
tions that had incorporated data from developed coun-
tries into their model. All studies included in this sub-
selection did use price data (for the goods and services
used in the intervention) from the country or region the
study was located in.
Economic evidence for interventions
We explicitly refrained from ranking the interventions
based on their cost-effectiveness ratio, in light of the
diversity in methods and outcome measures applied
across studies as well as the often considerable differ-
ences in methodological quality among studies (e.g.
transparency on type of costs included). Nevertheless,
we applied a simplified method–i.e. the so-called “hier-
archical decision matrix” (Table 1)–that has been
recommended to summarize results of systematic
reviews of economic evaluations [11]. As a first step,
outcomes on health benefits and costs against the com-
parator are extracted from the studies. Secondly, based
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out of 9 categories, depending on their cost/health out-
come profile. Each category defines how costs and
health benefits of the intervention compare to its com-
parator, i.e. higher, equal, below. Considering all possible
combinations, 9 categories are available for allocation–
reaching from “higher costs/lower health benefits” to
“less costs/higher health benefits”. Finally, the matrix
lists the different groups of intervention types/measures
and counts the number of studies within the different
cost/effectiveness categories. The categories are grouped
so that they inform the decision maker on recommenda-
tions, i.e. “reject intervention”, “neutral”, “incremental
analysis required”,o r“accept intervention”. Details of
results, including the reported cost-effectiveness ratios,
are listed in the additional material (Additional file 4–
Table of detailed results from included studies).
According to our matrix, no study recommended the
“rejection” of any intervention. Further, the vast majority
of studies recommend “incremental analysis” to decide on
the final acceptance of a measure, e.g. by defining an
appropriate cost-effectiveness acceptance threshold.
Only one intervention measure, i.e. health care delivery,
was uniformly recommended for “acceptance”, followed
by “procedures”, with 40% of those studies recommending
acceptance according to the matrix. This is not surprising,
since these interventions targeted mostly at reducing costs
while at least maintaining the quality of care.
Among all other types and measures of intervention,
no clear recommendation could be established and
incremental analysis is thus recommended for those
cases.
Discussion
Content aspects
The observed distribution of studies over time supports
the impression that the evaluation of cost-effective stra-
tegies to combat cardiovascular disease in developing
countries has been a neglected topic for decades. How-
ever, around the time of the release of the second edi-
tion of the report on Disease Control Priorities (DCP2,
April 2006), which among other issues covered interven-
tions to address chronic diseases in developing coun-
tries, the number of publications on cost-effective
strategies to reduce the burden caused by CVD in low-
and middle income countries increased significantly.
This could mean that the work on DCP2 has directly
led to the publication of relevant work and/or that it
has spurred the research interest in this area.
Nevertheless, large research gaps do remain in the
area of economic evaluations. While certain countries in
Latin America, Africa, Europe and South Asia have been
subject to some formal assessment, there are regions in
the world that have only been studied from an aggregate
perspective. These countries are typically located in the
regions of North Africa and the Middle East as well as
Central Asia, South Asia and East Asia. This may reflect
deficits in our research strategy (e.g. due to non-cover-
age of relevant languages), or–perhaps more likely–it
may indeed mean a paucity of research efforts.
Table 1 Hierarchical Decision Matrix of interventions to tackle CVD in low- and middle income countries (by type of
intervention and by type of intervention measure)
Reject
intervention
Incremental analysis required Neutral Incremental analysis required Accept
intervention
Health benefits - - ○ - ○ + ○ ++
Costs + ○ +- ○ +- ○ -
By type of Intervention
Case Management 0 0 0 1 0 5 2 0 0
Primary Prevention 0 0 0 0 0 9 1 0 1
Secondary Prevention 0 0 0 0 0 4 0 0 1
Various 0 0 0 0 0 7 2 0 0
By type of Intervention Measure
Pharmaceutical 0 0 0 0 0 12 1 0 1
Procedure 0 0 0 1 0 3 2 0 0
Health Education (Personal Level) 0 0 0 0 0 2 0 0 1
Social Marketing (Pop. based) 0 0 0 0 0 2 0 0 0
Medical Technology 0 0 0 0 0 2 0 0 0
Health Care Delivery 0 0 0 0 0 0 2 0 0
Various 0 0 0 0 0 4 0 0 0
+ above comparator ○ equal to comparator - below comparator
Numbers in cells are number of studies relevant to each permutation
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an answer to the question: which are the most cost-
effective ways of addressing CVD in developing coun-
tries? While we cannot provide a satisfactory answer to
this question, simply because the evidence base is too
limited, not enough transparent, and incomplete, we are
in a position to describe for which strategies there is
arguably strong evidence and where it is that research is
missing.
There is significant evidence for pharmaceutical strate-
gies to tackle risk factors as part of secondary preven-
tion and–in some cases–also for primary prevention.
While there appears to be a consensus on the utility (up
to a point) of certain pharmaceutical strategies in gen-
eral and the need for some form of their scaling up in
developing countries [12], the debate continues to
revolve around specific implementation and organisa-
tional issues [13]. This includes the discussion between
those advocating the targeting of patients with a single
but high risk factor (e.g. high blood pressure) on one
hand and those arguing for an overall absolute risk
approach (e.g. on the basis of 10-year risk of CVD),
independent of the particular risk factor, on the other
hand. There are also diverging views around the intro-
duction of a ‘poly-pill’, a medication consisting of multi-
ple pharmacological agents at a fixed dose, as a means
to provide more generic treatment options (compared
to treating each individual risk factor with a specific
drug and dose). Some argue that the poly-pill would
allow a broader population to access and use pharmaco-
logical care, due to lower requirements in risk factor
assessment and monitoring. Even though large trials in
developing countries have been undertaken to prove the
effectiveness of the poly-pill approach [14], its overall
consequences that would capture potential adverse
effects, the impact on health inequalities, the conse-
quences of mass medicalization for healthcare budgets
in developing countries, with a lot of resources allocated
to a few major medications, as well as the role of patient
compliance, still awaits a thorough assessment.
By contrast, there has been remarkably little research
coverage and discussion of non-clinical, population
based approaches, e.g. health promotion through social
marketing, or legislative actions as a way to tackle CVDs
in developing countries.
Apart from the methodological issues in evaluating
these interventions, at least two reasons may help
explain this bias in the research. First, research on popu-
lation based, non-clinical interventions is likely to be
subject to a market failure: private actors do not have
the incentive to engage in such research, because (a
large share of) the resulting knowledge would become a
public good that everybody could use, without having to
pay the often substantial research costs to arrive at that
knowledge. From a sheer economic efficiency (and not
even from a moral or public health) perspective, this
type of knowledge will be undersupplied compared to
the social optimum [15]. An analysis of the funding
sources of the articles included in our review shows that
out of the three studies reporting industrial support,
two evaluated pharmaceutical interventions and one a
medical technology. (Given the few studies reporting a
funding source, this observation may of course be of
limited generalizability.)
Second, primary data on the effectiveness of specific
population interventions typically does not exist for cer-
tain countries or regions. Since the results of interven-
tions targeted to change defined health behaviours or
implementing social marketing are highly dependent on
cultural, infrastructural and other system-related aspects,
scientists often argue that it is less feasible than in clini-
cal evidence to transfer such results from developed
regions to developing regions [16]. It is a widely held
assumption in pharmaceutical research that a drug
affecting biomedical processes would have approxi-
mately identical effects, irrespective of the ethnic con-
text in which it is applied. We will scrutinize this
hypothesis below, when considering the transferability of
results among countries and regions.
Despite our general endorsement of some form of
scaled up pharmaceutical support, it is also important to
be mindful of the limitations of such a strategy. This is
to do with the observation that any approach that
defines the benchmark risk level (e.g. on blood pressure)
as high as most current approaches recommend, inevita-
b l ym i s s e so u tt h et y p i c a l l yl a r g ea m o u n to fp e o p l et h a t
is below that threshold but nevertheless shows ailments
that are related to their (less than nominally “too high”)
risk factor levels (e.g. blood pressure) [17]. Even though
an approach assessing the total absolute risk of indivi-
duals would address some of the issues, it would imply
the allocation of (possibly disproportionately) large
resources to healthcare for the elderly population due to
the high contribution of age to these risk calculations.
Clinically managed chronic care often is expensive and
may be required for the remaining lifetime. An exten-
sion of the target group for treatment, though clinically
justified, would cause higher pressures on the already
constraint budgets of LIMCs. A population-based
approach, such as reducing salt intake, would at least in
principle also effect change in the entire population in
the long term and not only in the highest risk group.
Therefore including the larger group of beneficiaries in
this outcome calculation might in some cases render
such approaches attractive because it could be more
cost-effective. This could be the case even when the
overall population risk reduction is limited [18]. How-
ever, strong local level evidence of such a shift to proof
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in large-scale implementation and financing is still miss-
ing and requires further analysis.
In our search we found only a small number of stu-
dies assessing strategies to combat tobacco use. This is
surprising in light of the otherwise well-established evi-
dence on cost-effective strategies to address smoking-
related health loss. In particular, taxation and legislation
options have been rather well evaluated, certainly for
developed regions and countries but also in developing
countries [19]. The achieved reduction of smoking rates
is shown to have lowered the burden of disease caused
by CVD by about 36% in the UK [20]. One explanation
for the few studies we identified might lie in our search
strategy, which focused on studies concerning primarily
CVD. Smoking interventions, by contrast, might be
more often labeled in connection with lung diseases or
as an independent disease. Indeed, upon closer scrutiny,
more evidence for efficient strategies to reduce smoking
in developing countries does exist. Those include other
review articles, as for instance the 2003 study by Shi-
buya et al. [21] or the Chapter in the DCP2 publication
by Jha P et al. [22], both of which describe an increase
in tobacco tax as the most cost-effective strategy to
reduce smoking prevalence, followed by comprehensive
advertisement campaigns and bans on smoking in public
places.
In addition, we were surprised to realize that contrary
to an earlier review of ours on economic evaluations of
primary prevention of CVD in developed countries [5],
in the present review there were nearly no studies evalu-
ating the effects of statins–alone or in combination with
other drugs–on dyslipidemia. Neither for primary, nor
for secondary prevention did our search reveal any such
evidence for developing countries. Even though the first
statin, Lovastatin, went off-patent in the US and Europe
in 2001, it took until the patent expiration of the popu-
lar drug Simvastatin in 2006, for a statin (Simvastatin
for high risk patients) to be added to the World Health
Organization Model List of Essential Medicines in 2007
[23]. Until then, evaluations of strategies targeting dysli-
pidemia through statins might not have appeared useful
for developing countries, since broad access to the drug
had not been feasible. In addition, the diagnostic costs
for determining blood lipid levels are relatively high,
when compared for instance to measuring blood pres-
sure. Therefore targeting specifically dyslipidemia is less
feasible in developing countries, since the direct costs
(and infrastructure costs) for diagnosis and monitoring
of patients would require a considerable share of the
scarce resources.
I tm a yh a v ec o m ea sas u r p r i s et h a tw ef o u n dm o r e
studies in our review on primary prevention than on
secondary prevention of CVD. In interpreting these
results, however, it has to be acknowledged that we
used the definition of secondary prevention as stated by
the American Heart Association [10], i.e. meaning treat-
ing risk factors in patients with established cardiovascu-
lar disease (e.g. ischemic heart disease). Some other
disciplines, e.g. public health, tend to follow a broader
definition of secondary prevention that includes any
treatment of evident hypertension or dyslipidemia [24].
Another influential institution, i.e. the European Medi-
cines Agency [25], regards these definitions of preven-
tion in CVD as artificial and outdated and prefers to
discuss overall CVD risk on a continuum which needs
to be tackled by suitable measures.
Methodological aspects
In general, few of the studies adopted a comprehensive
perspective in their analysis. The more comprehensive a
study is, the easier it is for decision makers to compare
the intervention to other alternatives available for fund-
ing. This applies to the computation of health benefits
as well as to the economic perspective adopted. Only 12
out of the 33 studies included in our review used com-
prehensive units such as “life years gained” or the surro-
gate measure of “QALYs” or “DALYs” in their analysis.
The remaining studies preferred biomarkers or CVD
related incidents, which are easier to measure, but
harder to compare to other interventions within or out-
side the health care sector. No article applied a cost-
benefit approach.
Moreover, it is surprising to find that no study expli-
citly applied a societal perspective to the evaluation.
Both the cost-benefit method and the societal perspec-
tive would in principle be helpful approaches for deci-
sion makers, in particular in developing countries. In
these regions budgets are even more constraint and
investments in healthcare compete heavily with those in
other budgetary sectors, such as education or public
infrastructure. To support the decision maker in her
task of allocating resources across and within sectors,
m o r ec o m p r e h e n s i v ea n dh e n c em o r ec o m p a r a b l ee v a -
luations might have been desirable.
Modeling is a useful or indeed often necessary method
to produce economic evaluations in particular when cer-
tain data is missing or when long-term results represent
a core interest of the analysis. Eighteen out of 33 studies
included in our review used some form of modeling. In
modeling, one main decision concerns what effect mea-
sure to apply to compute intervention outcomes. In gen-
eral, in our review, both efficacy or effectiveness studies
are used. Revicki and Frank analyzed the importance of
both types of studies for pharmacoeconomic evaluations
[26]. While efficacy studies or RCTs demonstrate the
performance of an intervention under ideal and con-
trolled conditions, effectiveness studies show the impact
Suhrcke et al. BMC Public Health 2012, 12:2
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world” circumstances. Efficacy studies focus on the
internal validity of results and therefore accuracy of con-
clusions–however, their practical use is limited due to
potential lack in the generalisability of their results.
Effectiveness studies have a more real-life set-up and
lead to results of more practical value, increasing exter-
nal validity–at the potential cost of internal validity.
Revicki and Frank conclude that cost-effectiveness stu-
dies with RCTs “may provide a very precise answer to
the wrong question” [26]. In general, efficacy rates are
higher than effectiveness rates, therefore giving the deci-
sion maker a biased impression on success within his
population of concern. Due to the lower adherence to
treatment guidelines (by doctors and patients), co-mor-
bidities and limited patient monitoring, efficacy rates
usually drop in effectiveness trials [27,28]. Goldenberg
and Glueck [29] reviewed retrospective studies concern-
ing the goal attainment for statin therapy in managing
CVD and found that ~20% of patients did not receive
the necessary medication by their doctors when com-
pared to guidelines. Furthermore, only 50% of treated
patients achieved lipid-lowering goals with significant
consequences for CVD mortality and morbidity.
Another study focused on the patient side of adherence
in an Italian population of 10,890 patients [30]. Only
half of the patients who started on statins, continued to
take the medication after 1 year. In patients for primary
prevention of CVD, only 19% adhered to the regimen
prescribed by the doctor. Predictors for non-adherence
were younger age, total number of daily drug doses and
having multiple prescribing physicians. Similar adher-
ence rates can be found in the context of developing
countries. Bowry et al. [31] systematically reviewed stu-
dies on the adherence to cardiovascular medication in
resource-limited settings and found an average adher-
ence rate of 58% according to pill-count and self-report-
ing. Common predictors of non-adherence to
medication were poor knowledge, negative perceptions
about the medication, occurrence of side-effects, high
medication costs, and lack of family support. Factors
such as age, gender, lifestyle, complex treatment regi-
mens, and lack of access to health care services were
not consistently associated with non-adherence.
Revicki and Frank conclude that RCTs are a precondi-
tion for conducting effectiveness studies. However, for
providing the decision maker with relevant information
about the pharmacoeconomic outcomes of an interven-
tion, evaluations based on RCTs are of limited use, par-
ticular in a community setting [26].
In our sample of studies applying a modeling
approach, 17 out of 18 studies incorporated large RCTs
to calculate health benefit outcomes, either as single
source or in metaanalyses. Moreover, these studies were
all conducted in developed countries instead of the
country under analysis or a country with similar condi-
tions. This problem of transferring results will be dis-
cussed in detail below.
Transferability of results between regions–opportunities
and limitations
Conducting original economic evaluations for every
intervention in every LMIC is well beyond the means of
most developing countries’ monetary and human
resources. This general lack of capacity has to be con-
sidered when analyzing the studies and drawing conclu-
sions. For example, a third of studies included in our
review were conducted by authors at institutions in
solely developed countries (n = 11).
Hence the idea of transferring results from one coun-
try to another, in particular from developed to develop-
ing countries, has always been a potentially attractive
and fairly widely accepted alternative for researchers
and decision-makers. However, this approach also bears
several challenges, especially including differences in
health system costs across countries, differential effec-
tiveness of the same intervention, differential disease
prevalence, differential valuation of outcomes, and dif-
ferential efficiencies in the implementation of interven-
tions. In what follows we discuss these issues in light of
the existing cost-effectiveness evidence for CVD
interventions.
Use of external data
Disease modeling is widely applied in research on devel-
oping countries, as is shown extensively in our review.
Modeling approaches transfer data on disease epide-
miology, risk factor associations, relative clinical efficacy,
resource utilization, and unit cost from the country
w h e r et h eo r i g i n a ls t u d yt o o kp l a c et oat a r g e tc o u n t r y
o fi n t e r e s t .H a l fo ft h es t u d i e si n c l u d e di no u rr e v i e w
used this type of information in a model-based evalua-
tion of interventions. A disease model is expected to
incorporate as much data from the examined country
[32] as possible, e.g. information on disease and strength
and prevalence of risk factors, effectiveness of interven-
tions within the population, the resource use needed, as
well as prices for goods and services. Obviously, not all
data is always available for all developing countries for
reasons mentioned already above. This forces the scien-
tist to transfer data from countries where this informa-
tion is available to the country under analysis. Among
those 18 studies that did use modeling in our review,
none used external data on prices for services and
goods, three used epidemiological and risk factor data
from other countries, five used data on resource use
from other settings, and all 18 studies used aggregated
efficacy data from other healthcare settings to model the
cost-effectiveness of interventions, without accounting
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particular data on effectiveness (and efficacy) of multiple
and combined risk factor interventions is scarce for
developing countries. In particular, large RCTs or meta-
analyses of effectiveness studies are missing. Most esti-
mates for effectiveness in those cases were based on
data from developed countries. A study by Goeree et al.
[33] confirms that this is a general obstacle when trans-
ferring data among regions. Goeree et al. analyzed 40
economic evaluations, which had tried to transfer results
of studies to other geographic areas (not necessarily
developed to developing countries). They developed a
scoring system for the comprehensiveness of transfer-
ability (see Table 2 Modeling approaches based on the
three most commonly advocated transferability factors).
While costs (in 39 out of 40 studies) and (some)
resource use (28/40) was described as being most often
adapted to the local setting, clinical efficacy was directly
transferred from one geographic area to another. Only
two out of 40 studies used efficacy data from the target
country in their analysis. We applied the scoring system
to the articles included in our sub-selection of modeled
studies. Out of the 18 studies, none were category 1,s i x
would be classified as category 2,t w oa scategory 3,
seven as category 4, and none could fall into category 5.
Three studies did not supply enough information for an
explicit classification.
It can be expected that the effectiveness of risk factor
and disease interventions will differ between developing
and developed countries, given the often large differ-
ences in cultural, economic, infrastructural, and health
care aspects and differences in risk factor epidemiology.
In addition, biological differences may exist between
ethnic groups [34], possibly based on pharmacogenetics,
which might in some cases contribute to differences in
the efficacy of certain drugs.
There are no specific guidelines on how to handle this
type of uncertainty in modeling interventions for devel-
oping countries. While the guidelines for conducting a
CEA in the methods section of the DCP2 acknowledges
the lack of sufficient effectiveness data, no recommenda-
tions for transferring data from developed countries to
the context of low resource settings is provided. One
explanation suggests, however, that:
“Besides the quality of the evidence at its source, how
the results will apply to other settings matters, particu-
larly when the data are limited to high-income countries.
The more that outcomes depend on underlying biology,
the more the findings will apply to low- and middle-
income countries. Outcomes depending more on cultural
or environmental factors are less readily transferred and
require judgment and evidence as to their applicability
elsewhere.” [16]
This may reflect the fact that many researchers believe
or assume that clinical effects (in particular biological
effects) of the interventions are transferable across
health care systems but resource use and unit costs are
more location specific. This is often common practice in
HIC settings, while others tend to be more cautious in
this respect: the WHO-CHOICE project developed in
their guidelines a method on how to deal with differ-
ences in effectiveness. Effectiveness for developing coun-
tries is obtained by adjusting efficacy of clinical studies
in developed countries by a factor between 0 and 1,
based on the literature–or expert opinion as a last resort
to account for these uncertainties [35]. Even though this
method seems basic and its validity is not proven, it
emphasizes the need to consider these influences in
modeling [28].
As in all quantitative research, the use of valid and/or
appropriate mathematical models is key when evaluating
interventions in a generic way and for long-term [36].
Its critical assumptions may affect outcomes directly.
The validity of the used results from randomized con-
trolled trials for a particular study population may be
limited as there can be a bias [37]. The impact of both
the model and trial assumptions may be equally large. A
thorough assessment of the models used in the reviewed
papers, while desirable in principle, has on the whole
not been possible due to the lack of detailed information
on the precise model used in the studies. To allow more
transparent analysis and appreciation of the modeling,
we recommend, however, that future modeling analyses
employ check-lists on good-modeling practices [27].
Unal et al. [38] already systematically assessed the qual-
ity of 42 different models on cardiovascular disease and
stated that only 5 (12%) of them were comprehensive
enough, considering both all relevant risk factors and
Table 2 Modeling approaches based on the three most commonly advocated transferability factors (adopted from
Goeree et al.2007 [33])
Modeling approach Source of data by transferability factor
Category Clinical efficacy data Resource utilization data Unit cost data
Least to most country-specific analysis ↓ 1 Studied country only Studied country only Mixture of studied and target country
2 Studied country only Studied country only Target country only
3 Studied country only Mixture of studied and target country Target country only
4 Studied country only Target country only Target country only
5 Target country only Target country only Target country only
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in the quality and utility of mathematical models, in par-
ticular limited validation and calibration against
observed data. Quality standards for modeling studies
should be part of review processes (such as proposed by
ISPOR [39]).
Limitations
Our study has several limitations that need to be borne
in mind when interpreting the results. First, our search
strategy focused on cardiovascular disease treatment and
its prevention. We did not single out certain risk factors
to be included in the search string (as mentioned for
tobacco). Therefore, some studies that did not mention
CVD as intervention target might not be represented in
our systematic review. Secondly, our systematic review
is limited to a limited set of languages, i.e. German,
French, Spanish, and Italian. In particular the growing
literature in Chinese language, which is often not
abstracted in English, is neglected by our search strat-
egy. While recent and ongoing work of ours suggests
that there is indeed a wealth of studies on the effective-
ness of certain interventions targeting non-communic-
able diseases more generally published in the Chinese
language, the locally published cost-effectiveness research
remains scarce [40]. Nevertheless, we cannot completely
exclude the possibility that the inclusion of more lan-
guages might critically affect our results.
Conclusions
Even though the burden of cardiovascular disease in
developing countries has been a neglected topic for dec-
ades, the evidence about cost-effective strategies to com-
bat CVDs has been increasing since 2006, coinciding
with the publication of the DCP2 report. Nevertheless,
what economic evidence exists in low and middle
income countries is valuable but scarce when compared
to developed countries [5]. While the studies that we
reviewed were biased towards individual-level interven-
tions, mostly pharmaceutical, targeted at persons with
already established risk factors, approaches that follow a
population-based, non-clinical intervention strategy
hardly appear to have been submitted to a cost-effec-
tiveness analysis.
The presence of a majority of studies reporting the
cost-effectiveness of different pharmaceutical interven-
tions does not settle the debate as to whether the phar-
maceutical approach is the main one to pursue, as no
direct comparison to non-pharmaceutical interventions
was made. The full evaluation of rolling out a pharma-
ceutical strategy would also need to consider the poten-
tially prohibitive costs of scaling up screening for risk
factors and the infrastructure of supplying drugs for
identified persons and limited patient and system
compliance–all factors that are hard to gauge particu-
larly in developing countries. The experience in devel-
oped countries with extensive programmes to reduce
risk factors through large-scale pharmaceutical interven-
tions targeted at the high risk population for CVD,
instead of preventing this risk factor from occurring by
tackling the underlying causes, has increased the num-
ber of people requiring treatment. Providing medication
for all of them is stretching health care budgets of many
nations–as the example of hypertension shows [41].
A slight shift in the approach towards population-
based non-clinical policies has been observed in devel-
oped countries like the United Kingdom or Finland.
New strategies are applied to tackle the origin of the
epidemics, such as legislations for salt reduction and
food labeling [42]. As population-based interventions
are being tried and tested, more evidence will hopefully
emerge as to the true scope for them to make a differ-
ence to the CVD burden.
Our research also highlighted the most under-
researched regions of the world in this context. Even
though countries such as Armenia and Kazakhstan or
T u n i s i aa n dE g y p ts u f f e rf r o mah i g hb u r d e no fn o n -
communicable diseases (around 60-80% of years of life
lost (YLLs) [43]), those regions have not been the target
of economic evaluations of CVD interventions. Promot-
ing and incentivizing epidemiological and evaluation
research in those regions should be part of an interna-
tional health strategy on CVD risk reduction.
Another important insight concerns the data collec-
tion in developing countries. The methods used in the
economic evaluations vary significantly and the adher-
ence to common economic evaluation guidelines is less
than widespread. These are the main reasons why a
hierarchical listing of the study results is not feasible. A
large share of the studies included in our review used
mathematical modeling as a technique for economic
evaluation. The reasons as well as the opportunities and
limits have been described above. On one hand the
scientific community ought to consider more explicitly
how to handle the uncertainty (in effectiveness and
compliance) associated with mathematical modeling.
There is a need to identify affordable research designs
as alternatives to either modeling with data from rando-
mized controlled trials conducted in developed countries
or directly conducting randomized controlled trials in
developing regions. Other sources of data can contribute
in important ways to the evidence base (e.g., demon-
strating how a drug works in populations or under con-
ditions usually not studied in the trial)–t h ei d e ao f
producing so-called “Real-World data” (RWD). The
advantage of such effectiveness studies in informing the
decision maker have been laid out in the discussion. A
task force commissioned by the International Society for
Suhrcke et al. BMC Public Health 2012, 12:2
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identified the generation of RWD as a useful instrument
to support RCTs, validate outcomes across different
(sub-)populations or geographic regions, and to help
with “sound coverage and reimbursement decisions”
[44]. This data can be derived from large simple imple-
mentation trials, registry entries, or population health
surveys, acknowledging the loss of evidence strength. It
could well be a pragmatic and promising way forward in
the urgent quest for the best buys in tackling CVDs.
Obviously, any cost-effectiveness evidence hinges on
the presence of effectiveness evidence in the first place.
In this report we have not searched explicitly for studies
that focused on the sheer effectiveness of the interven-
tion. However, there exist other recent efforts that have
provided an overview of the evidence base on some of
the interventions that had not undergone an economic
evaluation. For example, a recent report published by
the WHO [45] on interventions on diet and physical
activity summarized all effectiveness evidence for differ-
ent interventions, assessed the quality of the studies
included and stated the degree of the effectiveness of
interventions. A large variety of common-sense and pro-
mising, effective measures to improve diet and physical
activity could be identified, including e.g. regulatory
policies, point-of-decision prompts to encourage–for
example–using stairs, or certain mass media campaigns.
Such reports on “what works” are likely to represent a
helpful first step in filling in the gaps in research on
cost-effectiveness and may be used for further economic
analysis in the future.
Additional material
Additional file 1: PRISMA checklist for systematic reviews.
Additional file 2: Search strings applied for the review.
Additional file 3: Descriptive table of results.
Additional file 4: Table of detailed results from included studies.
Acknowledgements
We gratefully acknowledge the partial funding obtained by the Institute of
Medicine (IOM), United States. We thank Kristen Danforth from the IOM for
essential help with the collection and extraction of the reviewed papers.
Many thanks also to Rachel Nugent and Ian Shemilt for very useful
comments on earlier drafts of the paper. This study was also supported by
the Centre for Diet and Activity Research (CEDAR), a UKCRC Public Health
Research Centre of Excellence. Funding from the British Heart Foundation,
Economic and Social Research Council, Medical Research Council, the
National Institute for Health Research, and the Wellcome Trust, under the
auspices of the UK Clinical Research Collaboration, is gratefully
acknowledged.
Author details
1Norwich School of Medicine, University of East Anglia, Norwich NR4 7TJ, UK.
2UKCRC Centre for Diet and Activity Research (CEDAR), Robinson Way,
Cambridge CB2 0SR, UK.
3Department of Medicine, University of Witten/
Herdecke, Faculty of Health, Alfred-Herrhausen-Str. 50, 58448 Witten,
Germany.
4Department of International Health, Johns Hopkins Bloomberg
School of Public Health, 615 N Wolfe Street, Baltimore, MD, USA.
Authors’ contributions
MS, TAB and LN conceived of the study and participated in its design. MS
and TAB conducted the literature review. TAB coordinated data retrieval,
extraction and analysis. All authors participated in the interpretation of
results and drafting of the manuscript. All authors read and approved the
final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 4 July 2011 Accepted: 3 January 2012
Published: 3 January 2012
References
1. Lopez A, Disease Control Priorities Project: Global Burden of Disease and Risk
Factors Washington, DC: World Bank Publications; 2006.
2. Leeder S, Raymond S, Greenberg H, Liu H, Esson K: A Race Against Time: The
Challenge of Cardiovascular Disease in Developing Economies New York:
Trustees of Columbia University; 2004.
3. Reddy KS, Yusuf S: Emerging epidemic of cardiovascular disease in
developing countries. Circulation 1998, 97:596-601.
4. World Bank: World Development Indicators 2007 Washington, DC: World
Bank Publications; 2007.
5. Schwappach DL, Boluarte TA, Suhrcke M: The economics of primary
prevention of cardiovascular disease–a systematic review of economic
evaluations. Cost Eff Resour Alloc 2007, 5:5.
6. Mulligan JA, Walker D, Fox-Rushby J: Economic evaluations of non-
communicable disease interventions in developing countries: a critical
review of the evidence base. Cost Effectiveness and Resource Allocation
2006, 4:7.
7. Schwappach DL, Boluarte TA: HEE-GER: a systematic review of German
economic evaluations of health care published 1990-2004. BMC Health
Serv Res 2007, 7:7.
8. Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group: Preferred
reporting items for systematic reviews and meta-analyses: the PRISMA
statement. PLoS Med 2009, 6:6.
9. Landis JR, Koch GG: The measurement of observer agreement for
categorical data. Biometrics 1977, 33:159-174.
10. Smith SC, Allen J, Blair SN, et al: AHA/ACC guidelines for secondary
prevention for patients with coronary and other atherosclerotic vascular
disease: 2006 update. Circulation 2006, 113:2363-2372.
11. Nixon J, Khan KS, Kleijnen J: Summarising economic evaluations in
systematic reviews: a new approach. BMJ 2001, 322(7302):1596-1598.
12. Gaziano TA, Galea G, Reddy KS: Scaling up interventions for chronic
disease prevention: the evidence. Lancet 2007, 370:1939-1946.
13. Gaziano TA: Reducing the growing burden of cardiovascular disease in
the developing world. Health Aff (Millwood) 2007, 26:13-24.
14. Yusuf S, Pais P, Afzal R, Xavier D, Teo K, Eikelboom J, et al: Effects of a
polypill (Polycap) on risk factors in middle-aged individuals without
cardiovascular disease (TIPS): a phase II, double-blind, randomised trial.
Lancet 2009, 373:1341-1351.
15. Dranove D: Is there underinvestment in R&D about prevention? J Health
Econ 1998, 17:117-127.
16. Musgrove P, Fox-Rushby J: Cost-effectiveness analysis for priority setting.
In Control Priorities in Developing Countries.. 2 edition. Edited by: Jamison D,
Breman J, Measham A, Alleyne G, Claeson M, Evans D et al. New York:
Oxford University Press and The World Bank; 2006:271-286.
17. Manuel DG, Lim J, Tanuseputro P, Anderson GM, Alter DA, Laupacis A, et al:
Revisiting Rose: strategies for reducing coronary heart disease. BMJ 2006,
332:659-662.
18. Neal B, Yangfeng W, Li N: The Effectiveness and Costs of Population
Interventions to Reduce Salt Consumption Geneva: World Health
Organization; 2006.
19. Chisholm D, Doran C, Shibuya K, Rehm J: Comparative cost-effectiveness
of policy instruments for reducing the global burden of alcohol, tobacco
and illicit drug use. Drug and Alcohol Review 2006, 25:553-565.
Suhrcke et al. BMC Public Health 2012, 12:2
http://www.biomedcentral.com/1471-2458/12/2
Page 12 of 1320. Unal B, Critchley JA, Capewell S: Explaining the decline in coronary heart
disease mortality in England and Wales between 1981 and 2000.
Circulation 2004, 109:1101-1107.
21. Shibuya K, Ciecierski C, Guindon E, Bettcher DW, Evans DB, Murray CJ: WHO
framework convention on tobacco control: development of an evidence
based global public health treaty. BMJ 2003, 327:154-157.
22. Jha P, Chaloupka F, Moore J, Gajalakshmi V, Gupta P, Peck R, et al: Tobacco
addiction. In Disease Control Priorities in Developing Countries.. 2 edition.
Edited by: Jamison D, Breman J, Measham A, Alleyne G, Claeson M, Evans D
et al. New York: Oxford University Press and The World Bank; 2006:869-886.
23. Kishore SP, Herbstman BJ: Adding a medicine to the WHO model list of
essential medicines. Clin Pharmacol Ther 2009, 85:237-239.
24. Tulchinsky TH, Varavikova A: Modes of prevention. The New Public Health. 2
edition. Burlington: Academic Press; 2008, 41-43.
25. Committee for Medicinal Products for Human Use (CHMP): Guidelines on
the Evaluation of Medicinal Products for Cardiovascular Disease Prevention
London: European Medicines Agency (EMA); 2008, Doc.Ref. EMEA/CHMP/
EWP/311890/2007.
26. Revicki DA, Frank L: Pharmacoeconomic evaluation in the real world.
Effectiveness versus efficacy studies. Pharmacoeconomics 1999,
15(5):423-434.
27. Godwin M, Ruhland L, Casson I, MacDonald S, Delva D, Birtwhistle R, et al:
Pragmatic controlled clinical trials in primary care: the struggle between
external and internal validity. BMC Med Res Methodol 2003, 3:28.
28. Cobden DS, Niessen LW, Barr CE, Rutten FF, Redekop WK: Relationships
among self-management, patient perceptions of care, and health
economic outcomes for decision-making and clinical practice in type 2
diabetes. Value Health 2009.
29. Goldenberg N, Glueck C: Efficacy, effectiveness and real life goal
attainment of statins in managing cardiovascular risk. Vasc Health Risk
Manag 2009, 5(1):369-376.
30. Deambrosis P, Saramin C, Terrazzani G, Scaldaferri L, Debetto P, et al:
Evaluation of the prescription and utilization patterns of statins in an
Italian local health unit during the period 1994-2003. Eur J Clin
Pharmacol 2007, 63(2):197-203.
31. Bowry AD, Shrank WH, Lee JL, Stedman M, Choudhry NK: A systematic
review of adherence to cardiovascular medications in resource-limited
settings. J Gen Intern Med 2011, 26(12):1479-1491.
32. Buxton MJ, Drummond MF, Van Hout BA, Prince RL, Sheldon TA, Szucs T,
et al: Modelling in economic evaluation: an unavoidable fact of life.
Health Econ 1997, 6:217-227.
33. Goeree R, Burke N, O’Reilly D, Manca A, Blackhouse G, Tarride JE:
Transferability of economic evaluations: approaches and factors to
consider when using results from one geographic area for another. Curr
Med Res Opin 2007, 23:671-682.
34. Brownley KA, Hurwitz BE, Schneiderman N: Ethnic variations in the
pharmacological and nonpharmacological treatment of hypertension:
biopsychosocial perspective. Hum Biol 1999, 71:607-639.
35. Evans DB, Edejer TT, Adam T, Lim SS: Methods to assess the costs and
health effects of interventions for improving health in developing
countries. BMJ 2005, 331:1137-1140.
36. Walls HL, Peeters A, Reid CM, Liew D, McNeil JJ: Predicting the
effectiveness of prevention: a role for epidemiological modeling. J Prim
Prev 2008, 29:295-305.
37. Gotzsche PC: Methodology and overt and hidden bias in reports of 196
double-blind trials of nonsteroidal antiinflammatory drugs in
rheumatoid arthritis. Control Clin Trials 1989, 10:31-56.
38. Unal B, Capewell S, Critchley JA: Coronary heart disease policy models: a
systematic review. BMC Public Health 2006, 6:213.
39. Weinstein MC, O’Brien B, Hornberger J, Jackson J, Johannesson M,
McCabe C, et al: Principles of good practice for decision analytic
modeling in health-care evaluation: report of the ISPOR Task Force on
Good Research Practices–Modeling Studies. Value Health 2003, 6:9-17.
40. World-Bank: Toward a Healthy and Harmonious Life in China: Stemming the
Rising Tide of Non-Communicable Diseases Beijing: Human Development
Unit, East Asia and Pacific Region, The World Bank; 2011.
41. Chobanian AV: Shattuck lecture. The hypertension paradox–more
uncontrolled disease despite improved therapy. N Engl J Med 2009,
361:878-887.
42. Karppanen H, Mervaala E: Sodium intake and hypertension. Prog
Cardiovasc Dis 2006, 49:59-75.
43. WHO Statistical Information System (WHOSIS): Geneva: World Health
Organization; 2009 [http://www.who.int/whosis/en/], accessed on 14-8-2009.
44. Garrison LP Jr, Neumann PJ, Erickson P, Marshall D, Mullins CD: Using real-
world data for coverage and payment decisions: the ISPOR Real-World
Data Task Force report. Value Health 2007, 10:326-335.
45. Anderson J, Parker W, Steyn N, Grimsrud A, Kolbe-Alexander T, Lambert E,
et al: Interventions on Diet and Physical Activity: What Works: Summary Report
Geneva: World Health Organization; 2009.
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1471-2458/12/2/prepub
doi:10.1186/1471-2458-12-2
Cite this article as: Suhrcke et al.: A systematic review of economic
evaluations of interventions to tackle cardiovascular disease in low- and
middle-income countries. BMC Public Health 2012 12:2.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Suhrcke et al. BMC Public Health 2012, 12:2
http://www.biomedcentral.com/1471-2458/12/2
Page 13 of 13